Skip to main content
. Author manuscript; available in PMC: 2016 Dec 15.
Published in final edited form as: Cell Rep. 2015 Nov 25;13(10):2159–2173. doi: 10.1016/j.celrep.2015.10.073

Figure 1. PU-H71 Is Cytotoxic in a Subset of AML Cells while Leaving Normal Blood Cells Unharmed.

Figure 1

(A) Growth of cells treated for 72 hr with PU-H71 (relative to untreated cells). PBL, peripheral blood lymphocytes.

(B) Cells were treated with or were not treated (control) with the Hsp90 inhibitor (Hsp90i), PU-H71. Percent annexin V+ cells relative to control after 48 hr treatment with PU-H71 is shown.

(C) Immunoblots showing cleaved PARP after 24 hr treatment with PU-H71.

(D) Percent increase in caspase-3, 7 activity assay after 24 hr treatment with PU-H71

(E) Immunoblots for Bcl-xL after 24 hr treatment with PU-H71

(F and G) Percent annexin V+ cells relative to control for primary AML cells (F) or cord blood mononuclear cells (MNCs) (G) after 48 hr treatment with PU-H71. (A, B, and D) Values denote mean ± SD (n = 4).

(F and G) Values denote SEM. See also Figure S1 and Tables S1 and S2.